+44 20 8123 2220
info@marketpublishers.com

Global Cancer Vaccine Market & Clinical Trial Insight

https://marketpublishers.com/r/G073617F1BDEN.html
Date: September 2015
Pages: 750
Price: US$ 4,000.00 (Single User License)
ID: G073617F1BDEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The concept of vaccines dates back to1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.

Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

+44 20 8123 2220
info@marketpublishers.com

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

Global Cancer Market Overview

Emergence of Personalized Cancer Vaccines

Platforms for Cancer Vaccines Delivery

Mechanism of Cancer Vaccines

Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country

Global Cancer Vaccine Clinical Pipeline: 298 Vaccines

Marketed Cancer Vaccines: 15 Vaccines

+44 20 8123 2220
info@marketpublishers.com

Regulatory Framework for Cancer Vaccines Development & Marketing

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

29. DISCONTINUED & SUSPENDED CANCER VACCINE DRUG CLINICAL PIPELINE INSIGHT

29.1 No Development Reported
29.2 Discontinued
29.3 Suspended

30. FDA REGULATORY FRAMEWORK FOR CANCER VACCINES DEVELOPMENT & MARKETING

30.1 Considerations for both Early and Late Phase Clinical Trials
  30.1.1 Patient Population
  30.1.2 Monitoring the Immune Response
  30.1.3 Biomarkers as Evidence Of Efficacy
  30.1.4 Adjuvants Used To Stimulate Immune Response
  30.1.5 Multi-Antigen Vaccines
  30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
  30.1.7 Concomitant and Subsequent Therapies
30.2 Considerations for Early Phase Clinical Trials
  30.2.1 Starting Dose and Dosing Schedule
  30.2.2 Booster and Maintenance Therapy
  30.2.3 Dose Escalation
  30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development
30.3 Considerations for Late Phase Clinical Trials
  30.3.1 Safety Profile from Early Phase Clinical Trials
  30.3.2 Endpoints
  30.3.3 Statistical Issues
  30.3.4 Control Issues
  30.3.5 Delayed Vaccine Effect
  30.3.6 Autologous Vaccine Trials
  30.3.7 Accelerated Approval Regulations

31. COMPETITIVE LANDSCAPE: BUSINESS OVERVIEW & PRODUCT PIPELINE

31.1 Advaxis
31.2 AVAX Technologies
31.3 Celldex Therapeutics
31.4 Dendreon Corporation

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

COMPANIES

Advaxis
AVAX Technologies
Celldex Therapeutics
Dendreon Corporation
Galena Biopharma
GlaxoSmithKline
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
KAEL-GemVax
Liponova
MedImmune
Merck
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Novartis
Peregrine Pharmaceuticals
Recombio
Roche
Sanofi
Seattle Genetics
Valeant Pharmaceuticals

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Cancer Vaccine Market & Clinical Trial Insight
Product link: https://marketpublishers.com/r/G073617F1BDEN.html
Price: US$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G073617F1BDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970